Premium
Insufficient evidence for cannabinoids in the treatment of mental disorders
Publication year - 2020
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30529
Subject(s) - cannabidiol , cannabis , medicine , psychiatry , effects of cannabis , synthetic cannabinoids , cannabinoid , receptor
The most comprehensive review to date of medicinal cannabinoids for the treatment of mental disorders has concluded that the evidence is insufficient to justify their use. A greater number of high‐quality trials is necessary to assess the safety and efficacy of medical cannabis and derivatives such as the increasingly popular cannabidiol (CBD), authors of the review and meta‐analysis stated. Results were published online Oct. 28 in Lancet Psychiatry .